466 related articles for article (PubMed ID: 34289038)
21. Addition of daratumumab to multiple myeloma backbone regimens significantly improves clinical outcomes: a systematic review and meta-analysis of randomised controlled trials.
Kiss S; Gede N; Hegyi P; Nagy B; Deák R; Dembrovszky F; Bunduc S; Erőss B; Leiner T; Szakács Z; Alizadeh H
Sci Rep; 2021 Nov; 11(1):21916. PubMed ID: 34754015
[TBL] [Abstract][Full Text] [Related]
22. Daratumumab plus lenalidomide and dexamethasone
Dimopoulos MA; San-Miguel J; Belch A; White D; Benboubker L; Cook G; Leiba M; Morton J; Ho PJ; Kim K; Takezako N; Moreau P; Kaufman JL; Sutherland HJ; Lalancette M; Magen H; Iida S; Kim JS; Prince HM; Cochrane T; Oriol A; Bahlis NJ; Chari A; O'Rourke L; Wu K; Schecter JM; Casneuf T; Chiu C; Soong D; Sasser AK; Khokhar NZ; Avet-Loiseau H; Usmani SZ
Haematologica; 2018 Dec; 103(12):2088-2096. PubMed ID: 30237262
[TBL] [Abstract][Full Text] [Related]
23. Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple Myeloma.
Costa LJ; Chhabra S; Medvedova E; Dholaria BR; Schmidt TM; Godby KN; Silbermann R; Dhakal B; Bal S; Giri S; D'Souza A; Hall A; Hardwick P; Omel J; Cornell RF; Hari P; Callander NS
J Clin Oncol; 2022 Sep; 40(25):2901-2912. PubMed ID: 34898239
[TBL] [Abstract][Full Text] [Related]
24. Real-world advantage and challenge of post-autologous stem cell transplantation MRD negativity in high-risk patients with double-hit multiple myeloma.
Tao Y; Jin S; Yang D; Pan M; Ouyang W; Liu Y; Wang Y; Zhang W; Mi J
BMC Cancer; 2024 Apr; 24(1):406. PubMed ID: 38565996
[TBL] [Abstract][Full Text] [Related]
25. Current treatment paradigm and survival outcomes among patients with newly diagnosed multiple myeloma in China: a retrospective multicenter study.
Fan H; Wang W; Zhang Y; Wang J; Cheng T; Qiu L; Wang X; Xia Z; An G
Cancer Biol Med; 2023 Jan; 20(1):77-87. PubMed ID: 36647781
[TBL] [Abstract][Full Text] [Related]
26. Measurable Residual Disease Assessment Using Next-Generation Flow in Patients With Relapsed and Refractory Multiple Myeloma Treated With a Combination of Carfilzomib, Lenalidomide, and Dexamethasone.
Yoroidaka T; Yamashita T; Murata R; Yoshihara K; Yoshihara S; Ueda M; Nakao S; Matsue K; Takamatsu H
Anticancer Res; 2023 Jan; 43(1):157-165. PubMed ID: 36585165
[TBL] [Abstract][Full Text] [Related]
27. Daratumumab, lenalidomide, and dexamethasone versus lenalidomide and dexamethasone alone in newly diagnosed multiple myeloma (MAIA): overall survival results from a randomised, open-label, phase 3 trial.
Facon T; Kumar SK; Plesner T; Orlowski RZ; Moreau P; Bahlis N; Basu S; Nahi H; Hulin C; Quach H; Goldschmidt H; O'Dwyer M; Perrot A; Venner CP; Weisel K; Mace JR; Raje N; Tiab M; Macro M; Frenzel L; Leleu X; Ahmadi T; Wang J; Van Rampelbergh R; Uhlar CM; Tromp B; Delioukina M; Vermeulen J; Usmani SZ
Lancet Oncol; 2021 Nov; 22(11):1582-1596. PubMed ID: 34655533
[TBL] [Abstract][Full Text] [Related]
28. [Role of minimal residual disease detection by multiparameter flow cytometry in newly diagnosed multiple myeloma: an analysis of 106 patients].
Deng SH; Xu Y; Sui WW; Wang HJ; Li ZJ; Wang TY; Liu W; Huang WY; Lyu R; Li J; Fu MW; Zou DH; An G; Qiu LG
Zhonghua Xue Ye Xue Za Zhi; 2018 May; 39(5):376-381. PubMed ID: 29779345
[No Abstract] [Full Text] [Related]
29. Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients.
Paiva B; Cedena MT; Puig N; Arana P; Vidriales MB; Cordon L; Flores-Montero J; Gutierrez NC; Martín-Ramos ML; Martinez-Lopez J; Ocio EM; Hernandez MT; Teruel AI; Rosiñol L; Echeveste MA; Martinez R; Gironella M; Oriol A; Cabrera C; Martin J; Bargay J; Encinas C; Gonzalez Y; Van Dongen JJ; Orfao A; Bladé J; Mateos MV; Lahuerta JJ; San Miguel JF;
Blood; 2016 Jun; 127(25):3165-74. PubMed ID: 27118453
[TBL] [Abstract][Full Text] [Related]
30. Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Chinese Patients with Relapsed or Refractory Multiple Myeloma: Phase 3 LEPUS (MMY3009) Study.
Lu J; Fu W; Li W; Hu J; An G; Wang Y; Fu C; Chen L; Jin J; Cen X; Ge Z; Cai Z; Niu T; Qi M; Sun S; Gai X; Liu W; Liu W; Yang X; Huang X
Clin Lymphoma Myeloma Leuk; 2021 Sep; 21(9):e699-e709. PubMed ID: 34108127
[TBL] [Abstract][Full Text] [Related]
31. Progression-Free Survival of Daratumumab Versus Bortezomib Triplet Combination With Lenalidomide and Dexamethasone in Transplant Ineligible Patients With Newly Diagnosed Multiple Myeloma: TAURUS Chart Review Study.
Gordan LN; Tan CR; Vescio R; Ye JC; Schinke C; Medhekar R; Fu AZ; Lafeuille MH; Thompson-Leduc P; Khare V; Reitan J; Milkovich G; Kaila S; Davies F; Usmani SZ
Clin Lymphoma Myeloma Leuk; 2024 Jan; 24(1):55-63. PubMed ID: 37838502
[TBL] [Abstract][Full Text] [Related]
32. A large meta-analysis establishes the role of MRD negativity in long-term survival outcomes in patients with multiple myeloma.
Munshi NC; Avet-Loiseau H; Anderson KC; Neri P; Paiva B; Samur M; Dimopoulos M; Kulakova M; Lam A; Hashim M; He J; Heeg B; Ukropec J; Vermeulen J; Cote S; Bahlis N
Blood Adv; 2020 Dec; 4(23):5988-5999. PubMed ID: 33284948
[TBL] [Abstract][Full Text] [Related]
33. Minimal Residual Disease Status as a Surrogate Endpoint for Progression-free Survival in Newly Diagnosed Multiple Myeloma Studies: A Meta-analysis.
Avet-Loiseau H; Ludwig H; Landgren O; Paiva B; Morris C; Yang H; Zhou K; Ro S; Mateos MV
Clin Lymphoma Myeloma Leuk; 2020 Jan; 20(1):e30-e37. PubMed ID: 31780415
[TBL] [Abstract][Full Text] [Related]
34. Treatment Regimens for Transplant-Ineligible Patients With Newly Diagnosed Multiple Myeloma: A Systematic Literature Review and Network Meta-analysis.
Facon T; San-Miguel J; Dimopoulos MA; Mateos MV; Cavo M; van Beekhuizen S; Yuan Z; Mendes J; Lam A; He J; Ammann E; Kumar S
Adv Ther; 2022 May; 39(5):1976-1992. PubMed ID: 35246820
[TBL] [Abstract][Full Text] [Related]
35. Daratumumab plus lenalidomide and dexamethasone in transplant-ineligible newly diagnosed multiple myeloma: frailty subgroup analysis of MAIA.
Facon T; Cook G; Usmani SZ; Hulin C; Kumar S; Plesner T; Touzeau C; Bahlis NJ; Basu S; Nahi H; Goldschmidt H; Quach H; Mohty M; Venner CP; Weisel K; Raje N; Hebraud B; Belhadj-Merzoug K; Benboubker L; Decaux O; Manier S; Caillot D; Ukropec J; Pei H; Van Rampelbergh R; Uhlar CM; Kobos R; Zweegman S
Leukemia; 2022 Apr; 36(4):1066-1077. PubMed ID: 34974527
[TBL] [Abstract][Full Text] [Related]
36. 3-weekly daratumumab-lenalidomide/pomalidomide-dexamethasone is highly effective in relapsed and refractory multiple myeloma.
Chim CS; Kumar S; Wong VKC; Ngai C; Kwong YL
Hematology; 2021 Dec; 26(1):652-655. PubMed ID: 34474661
[TBL] [Abstract][Full Text] [Related]
37. Daratumumab, Bortezomib, and Dexamethasone Versus Bortezomib and Dexamethasone in Patients With Previously Treated Multiple Myeloma: Three-year Follow-up of CASTOR.
Mateos MV; Sonneveld P; Hungria V; Nooka AK; Estell JA; Barreto W; Corradini P; Min CK; Medvedova E; Weisel K; Chiu C; Schecter JM; Amin H; Qin X; Ukropec J; Kobos R; Spencer A
Clin Lymphoma Myeloma Leuk; 2020 Aug; 20(8):509-518. PubMed ID: 32482541
[TBL] [Abstract][Full Text] [Related]
38. Real-world prognostic significance of attaining minimal residual disease negativity in newly diagnosed multiple myeloma.
Wang J; Li J; Zhang R; Li J; Chen L; Jin Y
Discov Oncol; 2024 Feb; 15(1):38. PubMed ID: 38367151
[TBL] [Abstract][Full Text] [Related]
39. Dynamics of minimal residual disease in patients with multiple myeloma on continuous lenalidomide maintenance: a single-arm, single-centre, phase 2 trial.
Diamond B; Korde N; Lesokhin AM; Smith EL; Shah U; Mailankody S; Hultcrantz M; Hassoun H; Lu SX; Tan C; Rustad EH; Maura F; Maclachlan K; Peterson T; Derkach A; Devlin S; Landau HJ; Scordo M; Chung DJ; Shah GL; Lahoud O; Thoren K; Murata K; Ramanathan L; Arcila ME; Ho C; Roshal M; Dogan A; Giralt SA; Landgren O
Lancet Haematol; 2021 Jun; 8(6):e422-e432. PubMed ID: 34048681
[TBL] [Abstract][Full Text] [Related]
40. Final analysis of a phase II trial of daratumumab, carfilzomib, lenalidomide, and dexamethasone in newly diagnosed multiple myeloma without transplant.
Derman BA; Cooperrider J; Rosenblatt J; Avigan DE; Rampurwala M; Barnidge D; Major A; Karrison T; Jiang K; Ramsland A; Kubicki T; Jakubowiak AJ
Blood Cancer J; 2024 May; 14(1):87. PubMed ID: 38811560
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
